State Street Corp Purchases 668,318 Shares of Celcuity Inc. (NASDAQ:CELC)

State Street Corp boosted its position in Celcuity Inc. (NASDAQ:CELC) by 152.2% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 1,107,415 shares of the company’s stock after acquiring an additional 668,318 shares during the period. State Street Corp owned 2.99% of Celcuity worth $16,512,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Braidwell LP lifted its position in shares of Celcuity by 71.2% during the third quarter. Braidwell LP now owns 884,306 shares of the company’s stock worth $13,185,000 after acquiring an additional 367,663 shares in the last quarter. Acuta Capital Partners LLC lifted its holdings in Celcuity by 3.6% during the 3rd quarter. Acuta Capital Partners LLC now owns 46,600 shares of the company’s stock worth $695,000 after purchasing an additional 1,600 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in Celcuity by 2,083.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 45,110 shares of the company’s stock worth $673,000 after purchasing an additional 43,044 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Celcuity by 226.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 221,671 shares of the company’s stock valued at $3,305,000 after buying an additional 153,712 shares in the last quarter. Finally, Prospera Private Wealth LLC bought a new stake in shares of Celcuity during the third quarter valued at about $35,000. 63.33% of the stock is owned by hedge funds and other institutional investors.

Celcuity Trading Up 1.0 %

Shares of CELC opened at $12.53 on Wednesday. Celcuity Inc. has a fifty-two week low of $11.51 and a fifty-two week high of $22.19. The firm has a market cap of $465.24 million, a price-to-earnings ratio of -4.80 and a beta of 0.74. The firm has a 50 day moving average price of $14.03 and a 200-day moving average price of $15.38. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35.

Analyst Ratings Changes

Several brokerages recently commented on CELC. Stifel Nicolaus boosted their price objective on shares of Celcuity from $39.00 to $42.00 and gave the company a “buy” rating in a research note on Monday, October 7th. HC Wainwright restated a “buy” rating and set a $27.00 price target on shares of Celcuity in a research report on Friday, November 15th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price objective on shares of Celcuity in a research report on Friday, November 15th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Celcuity has a consensus rating of “Buy” and an average price target of $29.17.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.